Company Lipigon Pharmaceuticals AB

Equities

LPGO

SE0015382072

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:22:20 2024-04-18 am EDT 5-day change 1st Jan Change
0.29 SEK -2.36% Intraday chart for Lipigon Pharmaceuticals AB -3.65% -32.71%

Business Summary

Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.

Number of employees: 7

Managers

Managers TitleAgeSince
Chief Executive Officer 45 10-04-05
Chairman 67 11-12-31
Director of Finance/CFO 54 22-12-31
Chief Operating Officer 60 20-12-31
Comptroller/Controller/Auditor - -
Corporate Officer/Principal 59 19-12-31

Members of the board

Members of the board TitleAgeSince
Chairman 67 11-12-31
Director/Board Member 52 20-12-31
Director/Board Member 64 22-12-31
Director/Board Member 61 22-05-18
Director/Board Member 54 19-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 126,422,281 89,026,825 ( 70.42 %) 0 70.42 %

Company contact information

Lipigon Pharmaceuticals AB

Tvistevägen 48 C

907 36, Umeå

+46 7 05 78 17 68

http://www.lipigon.se
address Lipigon Pharmaceuticals AB(LPGO)
  1. Stock Market
  2. Equities
  3. LPGO Stock
  4. Company Lipigon Pharmaceuticals AB